Tianjin Zhongxin Pharmaceutical Group Corporation Limited is the sole listed company in China that has listed both S-shares in Singapore and A-shares in China. Owning 50 branch companies and subsidiaries with holding and participating stock. Its sales revenue is reached 2.1 billion Yuan RMB a year. The business of Zhongxin covers a wide range of fields including Chinese patent medicines, Chinese medicinal materials, pharmaceutical raw materials and western medicines, bioengineering drugs and nutritious & health products, etc. with nearly 800 product varieties in 20-odd types of preparations being registered. The company has built up wholesale and retail system in various areas of Tianjin Municipality, with a marketing network extending to more than 30 countries and regions as well as all across China. The company’s key products are Suxiao Jiuxin Wan, Huoxiang Zhengqi Ruan Jiaonang, Zilong Jin Pian, Jinqi Jiangtang Pian, Weichang An Wan, Biqi Jiaonang, α-2b Interferon, Gliclazide, Te Zi She Fu, etc. and they enjoy high reputation in the medical community. As the company’s management is being perfected, the company makes some joint venture companies with some well-known pharmaceutical enterprises in the world such as Glax Smithkline America, Teva Israel, Baxter America, Shinpoong Seoul Korea, etc. so as to explore and go forward hand in hand for human health cause.